We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current XFOR market cap is 200.75M. The company's latest EPS is USD -0.6047 and P/E is -1.98.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.15M | -25.58M | -29.3M | -25.81M | -27.21M |
| Net Income | -21.87M | -29.1M | -24.02M | -55.71M | -2.31M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 3M | 0 | 0 | 0 |
| Operating Income | -47.8M | -59.87M | -85.11M | -88.08M | -107.52M |
| Net Income | -53.4M | -62.13M | -102.64M | -96.41M | -101.17M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 113.41M | 155.59M | 124.41M | 173.4M | 173.29M |
| Total Liabilities | 51.56M | 81.54M | 72.73M | 105.86M | 105.7M |
| Total Equity | 61.85M | 74.05M | 51.68M | 67.54M | 67.59M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 160.7M | 122.87M | 117.18M | 155.59M | 147.26M |
| Total Liabilities | 31.48M | 50.07M | 52.76M | 81.54M | 96.16M |
| Total Equity | 129.22M | 72.8M | 64.41M | 74.05M | 51.1M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -58.01M | -77.1M | -26.51M | -47.94M | -68.77M |
| Investing | -69k | -103k | -9k | -4.89M | -10.05M |
| Financing | 56.59M | 117.23M | -2.12M | 67.21M | 88.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -48.06M | -58.82M | -70.91M | -77.1M | -96.51M |
| Investing | 27.23M | -1.36M | -615k | -103k | -14.88M |
| Financing | 140.66M | 12.39M | 74.25M | 117.23M | 88.52M |
| Market Cap | 200.75M |
| Price to Earnings Ratio | -1.98 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.02 |
| Price to Book Ratio | 3.93 |
| Dividend Yield | - |
| Shares Outstanding | 167.29M |
| Average Volume (1 week) | 2.8M |
| Average Volume (1 Month) | 3.48M |
| 52 Week Change | -10.45% |
| 52 Week High | 2.575 |
| 52 Week Low | 0.5723 |
| Spread (Intraday) | 0.04 (3.33%) |
| Company Name | X4 Pharmaceuticals Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.x4pharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
